Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort StudyMulticenter Study Published on 2022-12-272023-07-11 Journal: Medicina [Category] COVID19(2023년), [키워드] COVID-19 Cytokine release syndrome In-hospital mortality. Tocilizumab [DOI] 10.3390/medicina59010053 PMC 바로가기 [Article Type] Multicenter Study
Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% confidence interval Analysis Baricitinib baseline benefit body mass index combination therapy Concomitant contributed control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Day Diabetes Mellitus examined faster greater hazard ratio immunomodulator immunomodulators IMPROVE in both group independent investigated median outcome Oxygen administration Patient patients Prognostic factors Remdesivir respiratory recovery retrospective Retrospective study severity single-center study standard treatment supplemental oxygen survival synergistic therapy Tocilizumab tocilizumab. treated two group [DOI] 10.1002/jmv.28037 PMC 바로가기
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patientsArticle Published on 2022-12-012022-11-15 Journal: Annals of Medicine [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] addition affecting alleviate antiviral medication antiviral medicine approved Baricitinib Care caused Clinical practice clinical recommendations Community courses COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 treatment COVID-19 treatments Critical deaths develop disease disorder drug Dyspnea effective effective drugs European European Medicines Agency European Union Evidence guidelines. Health healthcare hospital Hospitalization Hospitalized hospitalized patient hypoxia Intervention involved life-threatening lung involvement management Mild moderate molnupiravir monoclonal antibodies monoclonal antibody Most patient Multiorgan dysfunction New outcome public health recommendation Remdesivir Respiratory failure rheumatoid arthritis SARS-CoV-2 Septic shock severe symptom Symptom the disease the patient therapy Thromboembolism Tocilizumab treat Treatment treatment strategy union vaccination [DOI] 10.1080/07853890.2022.2133162 PMC 바로가기
‘Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM’ – Author’s replyArticle Published on 2022-11-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] administration elevated hospitalized COVID-19 patient Inflammatory Tocilizumab [DOI] 10.1016/j.cmi.2022.06.028 PMC 바로가기
“Ventilator-free days” composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysisArticle Published on 2022-11-012023-07-10 Journal: Heart & lung : the journal of critical care [Category] COVID19(2023년), [키워드] mechanical ventilation SARS-CoV-2 Tocilizumab Ventilator-free days. [DOI] 10.1016/j.hrtlng.2022.06.024 PMC 바로가기
Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORMArticle Published on 2022-11-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] Abstract administration Anti-interleukin-6 receptor COVID-19 elevated hospitalized COVID-19 patient Inflammatory randomized clinical trial Sub-groupe analyses Tocilizumab tocilizumab. [DOI] 10.1016/j.cmi.2022.06.013 PMC 바로가기
Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19Article Published on 2022-11-012022-11-15 Journal: European Journal of Hospital Pharmacy [Category] SARS, 진단, [키워드] 30-Day mortality Administered administration adverse event adverse events analysed Biomarker C-reactive protein clinical Clinical improvement cohorts of patient comparable complementary Complementary therapies coronavirus disease COVID-19 Critical Critical care decrease Efficacy epidemiologically group hospitalised Hypothesis inflammatory parameters knowledge lactate dehydrogenase medication Mortality onset of symptom outcome Patient patients with COVID-19 pharmacological treatment Pneumonia Primary outcome pulmonary medicine Quotient radiological radiological improvement Radiology. randomised controlled trial reductions in SaO_{2} secondary Severe COVID-19 pneumonia statistically significant difference subgroup subgroups the timing therapy Tocilizumab tocilizumab administration two group were recorded while [DOI] 10.1136/ejhpharm-2020-002669 PMC 바로가기
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumoniaArticle Published on 2022-10-282022-11-15 Journal: Medicina clínica [Category] 진단, [키워드] adults hospitalized COVID-19 Effect moderate-severe Pneumonia Standard of care Tocilizumab [DOI] 10.1016/j.medcli.2022.04.018 PMC 바로가기
Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulinArticle Published on 2022-10-202022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] abrogation Activation acute respiratory distress addition Alter ARDS cell-free DNA circulation Clinical treatment Corticosteroids Course COVID-19 COVID-19 patient Critically ill Dexamethasone dose-dependent elevated Ex vivo Factor functions healthy controls healthy donor healthy donors IL-8 inflammatory pathway Intravenous immunoglobulin Intravenous immunoglobulin (IVIG) lack Level Lung injury lung parenchyma modulate NET NETosis NETs neutrophil Neutrophil elastase Neutrophil extracellular trap neutrophil function Neutrophils not affect oxidative oxidative burst Patient Peripheral blood phagocytosis PMA pro-inflammatory function Proteins reactive oxygen specy reduced reduction severity syndrome targeting therapeutic therapeutic agent Tocilizumab tocilizumab. treated Treatment were assessed while with COVID-19 [DOI] 10.3389/fimmu.2022.993720 PMC 바로가기
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence TaskforceArticle Published on 2022-10-032022-11-15 Journal: The Medical journal of Australia [Category] COVID19(2023년), SARS, 진단, [키워드] Analysis anticoagulation Antiviral agents Baricitinib benefit change clinical clinical trial Combination coronavirus disease Corticosteroids COVID-19 disease disease severity drug treatment eight Endotracheal intubation Evidence facilitated Health include Inhaled maintain management Mild molnupiravir nine Patient people with COVID-19 positive airway pressure Primary Health Care prone positioning Prophylactic Prophylaxis Public public health. randomised recommendation recommendations Remdesivir Respiratory Support sarilumab subsequent supplemental oxygen Support supportive care systemic corticosteroids therapy Tocilizumab Treatment trials Venous Thromboembolism with COVID-19 [DOI] 10.5694/mja2.51718 PMC 바로가기